BiotechTube
Adaptin Bio

Adaptin Bio

Cambridge, United States· Est.
adaptinbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $55M

Overview

Adaptin Bio is a private, preclinical-stage biotech developing a novel 'hitchhiking' drug delivery platform called BRiTE to transport therapeutics across biological barriers like the blood-brain barrier. Its lead program targets EGFRvIII-positive gliomas, addressing a major unmet need in oncology. Founded in 2021 and led by a team with prior exit experience, the company is positioning its platform to enable targeted therapies for CNS, autoimmune, and cardiovascular diseases.

OncologyCentral Nervous System (CNS)

Technology Platform

BRiTE (Brain Bispecific T cell Engager) hitchhiking platform: a combination of a novel T cell engager and specifically manipulated polyclonal T cells designed to transport therapeutics across biological barriers like the blood-brain barrier.

Funding History

3
Total raised:$55M
Series A$35M
Seed$12M
Seed$8M

Opportunities

The BRiTE platform addresses the massive unmet need of delivering therapeutics across the blood-brain barrier, opening up the entire neuro-therapeutics market.
Its potential application beyond oncology to autoimmune and cardiovascular diseases creates a broad pipeline opportunity and significant partnering potential with large pharma.

Risk Factors

The novel 'hitchhiking' platform is unproven in humans, carrying high scientific and translational risk.
As a preclinical, private company, it faces significant financial risk dependent on raising capital, alongside intense competition in the drug delivery and neuro-oncology spaces.

Competitive Landscape

Adaptin Bio competes in the crowded and innovative field of blood-brain barrier drug delivery, facing companies exploring focused ultrasound, receptor-mediated transport, and other nanoparticle or antibody-based approaches. In glioblastoma, it will compete with other targeted therapies, including existing and next-generation T cell engagers and CAR-Ts attempting to overcome the BBB.

More companies in Drug Delivery & Formulation →More companies in United States →